ELDN Eledon: רווח למניה בשנים עשר החודשים האחרונים

Eledon Pharmaceuticals (ELDN) is optimizing production through external CDMO partners in California to minimize technical risks. The 12-month net income per share snapshot visualizes this process, and -0.80 becomes the new value for this metric. Market capitalization growth is supported by tegoprubart patents, while a strategic alliance with transplant centers helps develop effective methods for combating organ rejection.
פילוחים אנליטיים ודוחות נתונים של חברת Eledon (ELDN)

Net income per share over the last 12 months reflects the proportion of equity in the final financial result, allowing for an assessment of the business's actual profitability regardless of the total issuance volume. Analyzing this chart of net income per share over the last 12 months, an investor can see the impact of development costs for tegoprubart and clinical trials, which temporarily discount current earnings in favor of a future capture of the immunopharmaceuticals market for Eledon Pharmaceuticals (ELDN).